Navigation Links
Chemo for Late-Stage Cancer Patients May Be Unjustified
Date:6/9/2011

THURSDAY, June 9 (HealthDay News) -- Some patients with advanced cancer receive drugs that won't help them but could cause them harm, a U.S. study suggests.

University of Chicago researchers analyzed medical and pharmaceutical claims from 1,041 patients with metastatic colon cancer who were treated between January 2007 and June 2010. Of those patients, about one in eight received chemotherapy treatments that weren't supported by evidence from clinical trials or by clinical practice guidelines.

The researchers focused on three specific treatments. One had insufficient data to support its use, one had been shown to be ineffective, and one was not supported by data or a compelling rationale, according to the study.

The treatment with insufficient data involved the use of Avastin (bevacizumab) after a patient's cancer had progressed despite treatment with a combination of the drug and chemotherapy. The treatment shown to be ineffective was Xeloda (capecitabine) after cancer progression while being treated with the same class of drug. The treatment with no compelling rationale was Erbitux (panitumumab/cetuximab) after cancer progression while being treated with similar drugs.

The researchers said the patients who received these treatments were exposed to significant risk without proven benefits at an estimated cost of more than $2 million just for the drugs.

"Patients with advanced cancers that do no respond to standard therapies should either be looking for clinical trials, where there is a chance for benefit, or should have been thinking about shifting toward palliative care," study author Dr. Jonas De Souza, a hematology/oncology fellow, said in a university news release.

"Patients should not face the risks, discomforts and costs of aggressive and often quite toxic chemotherapy with treatment regimens that did not provide a benefit in previous studies," he added.

The study was presented this week at
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Tai chi could be key to overcoming cognitive effects of chemotherapy
2. Hormone test predicts ovarian function after chemotherapy for breast cancer
3. Taking Chemo Drug Continuously Delayed Lung Cancers Return
4. After Colon Cancer Surgery, Early Chemo May Pay Off
5. Following colorectal cancer surgery, longer delay before chemotherapy associated with worse survival
6. Antifungal drug delays need for chemo in advanced prostate cancer
7. Many patients fail to properly take oral chemo, leading to complications
8. Gene-modified stem cells help protect bone marrow from toxic side effects of chemotherapy
9. Chemo Combo May Help Stave Off Pancreatic Cancer Death
10. Genetic information may help predict likelihood of survival following chemotherapy for breast cancer
11. Genomic test shows promise as chemotherapy response, survival predictor for women with breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Chemo for Late-Stage Cancer Patients May Be Unjustified
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... ... array of instruments available for quantitative PCR (qPCR) in the last ... higher throughput and reduced operating costs. On the flipside, where do lab managers, ...
(Date:8/27/2015)... PA (PRWEB) , ... August 27, 2015 , ... ... Health Network , is one of just 20 adult-only medical centers in the ... for people with failing hearts and lungs. The Extracorporeal Life Support Organization ...
(Date:8/27/2015)... ... 27, 2015 , ... The Naderi Center is proud to announce that its ... procedure to improve submental fat. The first and only Food and Drug Administration ... Dr. Kulak is the only Board Certified surgeon in the D.C., Maryland, Virginia area ...
(Date:8/27/2015)... ... August 27, 2015 , ... More destinations and stores are becoming pet-friendly, ... Amica Insurance is sharing some tips to help your whole family travel safely and ... travel with pets each year. Amica is sharing the following tips from the American ...
(Date:8/27/2015)... , ... August 27, 2015 ... ... Swan Analysis signed a partnership agreement for quality market research promotion on ... elaborated by Black Swan Analysis. , Commenting on the partnership agreement, Natalie ...
Breaking Medicine News(10 mins):Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 2Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3
... CEL-SCI Corporation (NYSE AMEX: CVM ) announced today financial results ... results: , , ... of 41% compared to a net loss of $3,210,294 during the same quarter ... loss per common share for the quarter ended March 31, 2009 was $0.02 ...
... 15 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME/TSX: ... quarter ended March 31, 2009. Amounts, unless specified ... accordance with Canadian Generally Accepted Accounting Principles (Canadian ... 2009, the exchange rate was CAD$1.00=US$0.7928.Results of OperationsWe ...
... PARIS, FRANCE The International Union for Health ... Health Education (SOPHE) are pleased to release today special, ... and quality assurance systems of global capacity in health ... Education & Behavior (Vol. 36, No. 3, June ...
... Help Employers and Business Owners Plan for Pandemic ImpactPLYMOUTH ... hosting two free webinars on May 19, 2009 to ... Following the webinar Health Advocate will release a special ... summarizing steps for employers to take.Two experts - ...
... May 15 Within weeks, the University of ... campus that will provide a springboard for new discoveries, ... wise investment for U-M,s future.U-M,s purchase of the former ... North Campus will be completed on June 16, said ...
... of Medicine (BUSM) have found a high frequency ... the largest neonatal intensive care units (NICUs) in ... methods could reduce the vast number of hospital ... in the journal Infection Control and Hospital ...
Cached Medicine News:Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 2Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 3Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 4Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 5Health News:Cardiome Reports First Quarter Results 2Health News:Cardiome Reports First Quarter Results 3Health News:Cardiome Reports First Quarter Results 4Health News:Special journal issues released on global health promotion and health education 2Health News:Experts to Discuss Worksite Preparedness Measures During May 19th Pandemic Flu Webinars 2Health News:U-M Purchase of Former Pfizer Facility Nears Completion, Paving the Way For Research Expansion and Job Creation 2Health News:BUSM researchers find gram-negative rods in two Philippine neonatal intensive care units 2
(Date:8/27/2015)... CHICAGO and SOUTH SAN ... -- The Pulmonary Fibrosis Foundation (PFF) and ... announced that the organizations are partnering on a ... diagnostic experiences with interstitial lung diseases (ILDs), including ... Patient Journey (INTENSITY) survey will assess the steps ...
(Date:8/27/2015)... MENLO PARK, Calif. , Aug. 27, 2015 /PRNewswire/ ... the "Company"), a biopharmaceutical company focused on the development ... it will release its year-end financial results for the ... 4, 2015. DelMar,s management team will ... for investors, analysts and other interested parties on Friday, ...
(Date:8/27/2015)... August 27, 2015 The global ... reach USD 3.96 billion by 2022, according to a ... of chronic venous disorders such as deep vein thrombosis, ... serve as the key driver.      (Logo: ... injuries are also expected to boost market growth over ...
Breaking Medicine Technology:Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 2DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 3Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 2Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 3Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 5
... ANGELES, April 17, 2007 /PRNewswire/ -- Researchers from ... presented,strong evidence today that an antibiotic typically prescribed ... types of cancers. , Q. Ping Dou, Ph.D., ... lab announced the findings of their study showing,that ...
... LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - ZIOPHARM ... of preclinical,data strongly supportive of the development ... demonstrates very high,bioavailability when administered orally; in ... well suited to oral,administration. These data were ...
Cached Medicine Technology:Alzheimer's Drug Shows Promise in Fighting Cancer 2ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR 2ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR 3
Express Elyte Systems....
... 1650 has minimal requirements for ... 2 L/test), reagent consumption (as ... water consumption (25 L/hour) - ... universal rack handler facilitates continuous ...
Iron Total (TIBC) (Iron Buffer + Iron Color=Std.). An Automated analyzer test kits....
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
Medicine Products: